Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin Melt for Nocturnal Polyuria
2011-000666-35Phase 3
Key facts
- Status
- Terminated
- Start
- Feb 2011
- Countries
- 1
- Sponsor
- Ghent University Hospital
- Modality
- Small Molecules, Peptides
- Drugs
- desmopressin
- Conditions
- nocturnal polyuria (NP)nocturia
01
Overview
Phase 3, open-label, single-arm trial of desmopressin in nocturnal polyuria (NP) and nocturia, sponsored by Ghent University Hospital. Primary endpoints: Urine production, Concentrating capacity of desmopressin melt and 1 more. Started Feb 2011; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Desmopressin melt 120 µg
Single-group desmopressin melt monotherapy for patients with nocturnal polyuria.
03
Who it enrols
Adults with nocturnal polyuria/nocturia providing written informed consent; patients with known hypersensitivity or anaphylactic reaction to desmopressin or its components are excluded.
04
Endpoints
Primary
Urine production
Concentrating capacity of desmopressin melt
Side effects
Beyond the preview
Go deeper on 2011-000666-35.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000666-35.